Literature DB >> 19718796

Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.

Peng Zou1, Songbo Xu, Stephen P Povoski, Anna Wang, Morgan A Johnson, Edward W Martin, Vish Subramaniam, Ronald Xu, Duxin Sun.   

Abstract

Anti-TAG-72 monoclonal antibodies target the tumor-associated glycoprotein (TAG)-72 in various solid tumors. This study evaluated the use of anti-TAG-72 monoclonal antibodies, both murine CC49 and humanized CC49 (HuCC49deltaCH2), for near-infrared fluorescent (NIR) tumor imaging in colorectal cancer xenograft models. The murine CC49 and HuCC49deltaCH2 were conjugated with Cy7 monofunctional N-hydroxysuccinimide ester (Cy7-NHS). Both in vitro and in vivo anti-TAG-72 antibody binding studies were performed. The in vitro study utilized the human colon adenocarcinoma cell line LS174T that was incubated with Cy7, antibody-Cy7 conjugates, or excessive murine CC49 followed by the antibody-Cy7 conjugates and was imaged by fluorescence microscopy. The in vivo study utilized xenograft mice, bearing LS174T subcutaneous tumor implants, that received tail vein injections of Cy7, murine CC49-Cy7, HuCC49deltaCH2-Cy7, or nonspecific IgG-Cy7 and were imaged by the Xenogen IVIS 100 system from 15 min to 288 h. The biodistribution of the fluorescence labeled antibodies was determined by imaging the dissected tissues. The in vitro study revealed that the antibody-Cy7 conjugates bound to LS174T cells and were blocked by excessive murine CC49. The in vivo study demonstrated that murine CC49 achieved a tumor/blood ratio of 15 at 96 h postinjection. In comparison, HuCC49deltaCH2-Cy7 cleared much faster than murine CC49-Cy7 from the xenograft mice, and HuCC49deltaCH2-Cy7 achieved a tumor/blood ratio of 12 at 18 h postinjection. In contrast, Cy7 and Cy7 labeled nonspecific IgG resulted in no demonstrable tumor accumulation. When mice were injected with excessive unlabeled murine CC49 at 6 h before the injection of murine CC49-Cy7 or HuCC49deltaCH2-Cy7, both the intensity and retention time of the fluorescence from the tumor were reduced. In summary, the Cy7 labeled murine CC49 and HuCC49deltaCH2 demonstrate tumor-targeting capabilities in living colorectal cancer xenograft mice and provide an alternative modality for tumor imaging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19718796      PMCID: PMC2888669          DOI: 10.1021/mp9000052

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  52 in total

1.  In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.

Authors:  Diane E Milenic; Kayhan Garmestani; Lara L Chappell; Ekaterina Dadachova; Alexander Yordanov; Dangshe Ma; Jeffrey Schlom; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2002-05       Impact factor: 2.408

Review 2.  Introduction to the physics of molecular imaging with radioactive tracers in small animals.

Authors:  Michael A King; P Hendrik Pretorius; Troy Farncombe; Freek J Beekman
Journal:  J Cell Biochem Suppl       Date:  2002

3.  Radioimmunoguided surgery for colorectal cancer.

Authors:  D J Bertsch; W E Burak; D C Young; M W Arnold; E W Martin
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

4.  Five-year survival after extended resection of colon cancer.

Authors:  B Gardner
Journal:  J Surg Oncol       Date:  1987-04       Impact factor: 3.454

5.  Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system).

Authors:  A Sardi; M Workman; C Mojzisik; G Hinkle; C Nieroda; E W Martin
Journal:  Arch Surg       Date:  1989-01

6.  Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients.

Authors:  Jim Xiao; Sara Horst; George Hinkle; Xianhua Cao; Ergun Kocak; Jing Fang; Donn Young; M Khazaeli; Doreen Agnese; Duxin Sun; Edward Martin
Journal:  Cancer Biother Radiopharm       Date:  2005-02       Impact factor: 3.099

7.  Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue.

Authors:  A Molinolo; J F Simpson; A Thor; J Schlom
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

8.  Sentinel lymph node mapping of the gastrointestinal tract by using invisible light.

Authors:  Edward G Soltesz; Sungjee Kim; Sang-Wook Kim; Rita G Laurence; Alec M De Grand; Cherie P Parungo; Lawrence H Cohn; Moungi G Bawendi; John V Frangioni
Journal:  Ann Surg Oncol       Date:  2006-01-31       Impact factor: 5.344

9.  Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.

Authors:  Lakshmi Sampath; Sunkuk Kwon; Shi Ke; Wei Wang; Rachel Schiff; Michel E Mawad; Eva M Sevick-Muraca
Journal:  J Nucl Med       Date:  2007-09       Impact factor: 10.057

10.  Radioimmunoguided surgery in recurrent colorectal cancer: the role of carcinoembryonic antigen, computerized tomography, and physical examination.

Authors:  A Sardi; C M Agnone; C A Nieroda; C Mojzisik; G Hinkle; P Ferrara; W B Farrar; J Bolton; M O Thurston; E W Martin
Journal:  South Med J       Date:  1989-10       Impact factor: 0.954

View more
  43 in total

1.  Improved speciation characteristics of PEGylated indocyanine green-labeled Panitumumab: revisiting the solution and spectroscopic properties of a near-infrared emitting anti-HER1 antibody for optical imaging of cancer.

Authors:  Aaron Joseph L Villaraza; Diane E Milenic; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2010-11-12       Impact factor: 4.774

2.  Detection limits of intraoperative near infrared imaging for tumor resection.

Authors:  Greg M Thurber; Jose-Luiz Figueiredo; Ralph Weissleder
Journal:  J Surg Oncol       Date:  2010-12-01       Impact factor: 3.454

3.  Mesoscale nanoparticles selectively target the renal proximal tubule epithelium.

Authors:  Ryan M Williams; Janki Shah; Brandon D Ng; Denise R Minton; Lorraine J Gudas; Christopher Y Park; Daniel A Heller
Journal:  Nano Lett       Date:  2015-03-26       Impact factor: 11.189

4.  Near-infrared molecular probes for in vivo imaging.

Authors:  Xuan Zhang; Sharon Bloch; Walter Akers; Samuel Achilefu
Journal:  Curr Protoc Cytom       Date:  2012-04

5.  Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence.

Authors:  Fang Wu; Suraj G Bhansali; Wing Cheung Law; Earl J Bergey; Paras N Prasad; Marilyn E Morris
Journal:  Pharm Res       Date:  2012-02-29       Impact factor: 4.200

6.  Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma.

Authors:  Yang Zhang; Zhan-sheng Deng; Ming-mei Liao; Ning Wang; Xiao-qing Zhang; Hai-yang Yu; Yang-de Zhang
Journal:  Pathol Oncol Res       Date:  2012-03-21       Impact factor: 3.201

Review 7.  Recent trends in antibody-based oncologic imaging.

Authors:  Sukhwinder Kaur; Ganesh Venktaraman; Maneesh Jain; Shantibhusan Senapati; Pradeep K Garg; Surinder K Batra
Journal:  Cancer Lett       Date:  2011-10-20       Impact factor: 8.679

8.  Increased Active Tumor Targeting by An αvβ3-Targeting and Cell-Penetrating Bifunctional Peptide-Mediated Dendrimer-Based Conjugate.

Authors:  Pengkai Ma; Huajun Yu; Xuemei Zhang; Hongjie Mu; Yongchao Chu; Ling Ni; Pingping Xing; Yiyun Wang; Kaoxiang Sun
Journal:  Pharm Res       Date:  2016-11-15       Impact factor: 4.200

9.  Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model.

Authors:  Greg M Thurber; Jose L Figueiredo; Ralph Weissleder
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

10.  Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial glioma of athymic mice.

Authors:  Heling Zhou; Kate Luby-Phelps; Bruce E Mickey; Amyn A Habib; Ralph P Mason; Dawen Zhao
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.